Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

Inclusion Criteria

• •The patient must have successfully completed the full 78-week duration of the double-blind CL-758007 study.
• •Male or female (age 50 years and older): Female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal).
• •Patient must be living in the community with a reliable caregiver. Participant living in an assisted living facility may be included if study medication intake is supervised and participant has a reliable caregiver.
• •The patient must be presenting a reasonably good nutritional status.
• •Signed inform consent from the patient or legal representative.